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TRYPSIN INHIBITION BY FERROCENE
Zoran Z. Kukrić and Mirjana M. Žabić
Many transition metals and their complexes show inhibitory effect on some proteolytic 
enzimes, including trypsin. Their inhibitory activity is based on the direct binding to the 
active site of trypsin, mimicking  formation of a ﬁve-coordinate transition state  required 
for the reaction.
The inﬂuence of ferrocene on trypsin activity using N-α-benzoyl-DL-arginine p-
nitroanilide as a substrate was investigated. Ferrocene was selected as a potential inhibitor 
because it belongs to the family of organometallic, so called “sandwich” compounds, and 
its cyclopentadienyl rings might have an appropriate geometry. It was found that ferrocene 
decreases trypsin activity and the Ki  for ferrocene was found to be 39.8 µM.
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INTRODUCTION
Considering that the dysbalance of enzyme activity can cause serious illnesses, the 
inhibitors that can selectively control proteolytic activity could be very useful for the 
prevention of such illnesses. 
Proteolytic enzymes, that are devided into four major classes - aspartic, cysteine, 
metallo, serine, catalyze both intracellular and extracellular peptide cleavages during nu-
merous physiological processes, including digestion, fertilization, growth, differentiation, 
immunological defence, wound healing, etc.
Proteases are also vital in the propagation of most desease processes. Thus selective 
inhibition of prote  ases (1) is increasingly being targeted for the treatment of cancers (2-
4), parasitic, fungal and viral infec  tions, e.g. malaria (5,6), C. albicans (7,8), HIV (9-12), 
hepatitis C (13,14), herpes (15,16), common cold (17), inﬂammatory, immunological and 
respiratory conditions (18-21), cardiovascular (22) and degene  rative disorders, including 
Alzheimer’s disease (23,24).
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There are now many designed potent and selective protease inhibitors that slow down 
or halt disease progression (25), HIV-1 protease inhibitors being probably most studied 
nowadays (9-12).
Proteolytic enzymes are not completely speciﬁc, and besides a peptide bond hydro-
lysis, most of them also catalyze a different but related reaction, e.g. the hydrolysis of an 
ester bond. They differ greatly in their degree of substrate speciﬁcity, even within the same 
class. Thus serin proteases trypsin, elastase and chymotrypsin have about 60% identical 
primary structure, very similar 3D structure, nearly identical catalytic mechanism includ-
ing tetrahedral transition state and the same catalytic triad (Ser-His-Asp).
However, these enzymes differ markedly in substrate speciﬁcity. Chymotrypsin re-
quires an aromatic or bulky nonpolar side chain on the amino side of the scissile bond 
(next to Phe, Tyr, Trp). Trypsin requires a lysine or arginine residue, while elastase prefers 
small, hydrophobic residues such as alanine. X-ray stu  dies have shown that these different 
speciﬁcities are due to quite small structural differences in the bin  ding site. In chymotryp-
sin, a nonpolar pocket serves as a niche for the aromatic or bulky nonpolar side chain. In 
trypsin, one residue in this pocket is different from chymotrypsin: a serine is replaced by 
an aspartate (Asp 189). This aspartate in the nonpolar pocket of trypsin can form a strong 
electrostatic bond with a positively charged lysine or arginine side chain of a substrate. In 
elastase, the pocket does not exist, because the two glycine residues lining it in chymo-
trypsin are replaced by the much bulkier valine and threonine.
Probably, the most investigated serine protease is trypsin. Natural trypsin inhibitor 
is pancreatic poly  peptide which binds very tightly to its active site, thus halting further 
proteolysis. This enzyme-inhibitor complex is exceptionally stable and its dissociation is 
very slow because its structure is almost perfectly complementary to that of the active site. 
There is a number of more or less potent trypsin inhibitors repor  ted in the literature. Most 
of them are polypeptides (isolated or synthesized), and some of them are simple organic 
compunds, such as benzamidine. Most of these inhibitors have positively charged nitrogen 
atom which interacts with negatively charged Asp 189 in the trypsin’s primary substrate 
binding pocket.
An alternative approach to the development of clinically useful protease inhibitors 
that is being investi  gated recently (26) utilizes coordination chemistry of transition metal 
ions and their complexes.
It was found that ﬁve-coordinated titanyl sulfate completely and irreversibly blocks 
trypsin (27). The direct binding of Ti(IV) to trypsin was made possible by the presence of 
a free carboxyl group at the bottom of the substrate binding pocket of the enzyme (Asp 
189) and the ﬁve-coordinate geometry of TiO(SO4)(H2O).
It has been known that metallocenes of transition metals exhibit antitumour activity 
(28). These com  plexes have shown antiproliferative activity against sarcoma, melanoma, 
colon and lung carcinoma (29).
The applications of ferrocene in chemistry are indeed vast: it is being used in electro-
chemical enzyme biosensors (30), in catalysis of chiral compounds (31), etc. Ferrocene 
based polymers have been shown to exhibit interesting electrochemical, optical, thermal, 
morphological, pharmacological and magnetic properties (32).
Also, ferrocene unit is being inserted into the structure of already known drugs, mak-
ing them more effective. The most recent example is the development of ferrocifens (33), 
ferrocen-substituted tamoxifen analogs, which are proven to be not only more effective 
against breast cancer than tamoxifen, but also with less acute toxicity. Ferrocene by itself 205
had no effect on the proliferation of the breast cancer cells. The mechanisms of ferrocifens’ 
action is not yet fully understood, although recent studies indicate that the ferro  cifens, like 
their purely organic equivalents, act by changing the conformation of the receptor pro  tein. 
In addition, when ferrocifen binds to a receptor, an oxidant/antioxidant mechanism comes 
into pro  minant play, because carcinogenic and metastatic processes are inhibited by anti-
oxidants and free-radical scavengers. By inserting a ferrocenyl group into the side chain 
of chloroquine, (a drug used for malaria treatment), much more potent and safer hybrid 
compound, called ferroquine, was produced (33).
Ferrocene, an organometallic compoud with «sandwich» structure, has been chosen to 
study its potential inhi  bitory action on trypsyn because of the cyclopentadienyl rings that 
have ﬁve-coordinate geometry.
EXPERIMENTAL
Materials
a)  Chemicals used in this study were: Trypsin (Sigma, activity 1000-1500 BAEE units/
mg solid, from porcine pancreas), BAPNA (N-α-benzoyl-DL-arginine p-nitroanilide), 
≥ 98% (Fluka), Tris buffer (Tris(hydroxymethyl)aminomethane, Lachema).
b)  Solution preparation: Tris-HCl buffer at pH 8.2 was prepared by dissolving 6.05 g 
of Tris and 2.53 g of CaCl2 in 900 mL of distilled water, and the pH was adjusted 
with dilute HCl and made up to 1000 mL with distilled water. Trypsin solutions were 
prepared by dissolving trypsin in 0.001M HCl. BAPNA was completely dissolved in 
dimethyl sulfoxide (1.5 mL DMSO/ 100 mg BAPNA) and then made up with Tris 
buffer, pH 8.2
Kinetic studies of trypsin catalized hydrolysis with or without inhibition
The trypsin catalyzed hydrolysis of BAPNA was investigated spectrophotometrically 
(410 nm), at pH 8.2 (50 mM Tris-HCl buffer) and 37oC in the absence and presence of 
ferrocene. 
Reaction mixture consists (Table 1) of 1 ml of Tris buffer and 5 ml of a trypsin solu-
tion which was incubated at 37oC for 5 min. Then 20 ml of BAPNA solution was added; 
5 ml aliquots were taken at 0, 2 and 5 minutes of incubation and transferred to test tubes 
containing 0.1 ml of 30% acetic acid. In this way the reaction was terminated, and the 
released yellow-coloured p-nitroanilin was measured at 410 nm (34). 
In the experiments with inhibitor, 1 ml of ferrocene solution was added after 5 minutes 
of trypsin-Tris buffer incubation, followed by another 5 minutes of incubation at 37oC, 
before the substrate solution was added (Table 2). Wavelength 410 nm was selected based 
on the UV-VIS absorption spectra of BAPNA, ferrocene and p-nitroaniline.
Molar extinction coefﬁcients were determined for BAPNA (ξ= 30.5 M-1cm-1), fer-
rocene (ξ= 42.6 M-1cm-1) and p-nitroaniline (ξ= 9800 M-1cm-1; literature value ξ= 10 000 
M-1cm-1 was used in calculations).
The reaction velocity (v) was caclulated as initial velocity.
In determining Ki the reaction mixture consisted of 1 ml of Tris buffer, 5 ml of trypsin 
solution, 20 ml of substrate solution, with two different substrate concentrations (Table 3).206
Table 1. Reaction mixture preparation for the reaction velocity determination
Sample 
#
Tris buffer
(ml)
Trypsin
(14.706 µM) (ml)
BAPNA
(ml)
BAPNA
(mM)
1 1.00 5.00 20.00 4.5988
2 1.00 5.00 20.00 3.0720
3 1.00 5.00 20.00 1.4716
4 1.00 5.00 20.00 0.9197
5 1.00 5.00 20.00 0.3532
6 1.00 5.00 20.00 0.1839
Table 2. Reaction mixture preparation for the reaction velocity
determination in the presence of ferrocene
Sample
#
Tris buffer
(ml)
Trypsin
(14.706µM) 
(ml)
Ferrocene
(1.1503mM)
(ml)
BAPNA
(ml)
BAPNA
(mM)
1 1.00 5.00 1.00 20.00 4.7828
2 1.00 5.00 1.00 20.00 3.1916
3 1.00 5.00 1.00 20.00 1.5314
4 1.00 5.00 1.00 20.00 0.9566
5 1.00 5.00 1.00 20.00 0.3675
6 1.00 5.00 1.00 20.00 0.1913
Table 3. Reaction mixture preparation for Ki determination 
Sample
#
Tris buffer
(ml)
Trypsin
(14.706 µM)
(ml)
Ferrocene
(ml)
Ferrocene
(mM)
BAPNA
S1 and S2
(ml)
1 1.00 5.00 1.00 1.91357 20.00
2 1.00 5.00 1.00 1.53086 20.00
3 1.00 5.00 1.00 1.15029 20.00
4 1.00 5.00 1.00 0.76839 20.00
5 1.00 5.00 1.00 0.38190 20.00
Substrate concentrations in the reaction mixture were 2.3641 mM (S1) and 3.5428 
mM (S2).207
RESULTS AND DISCUSSION
Determination of the Michaelis constant
a)  In the absence of ferrocene
The initial velocity at various substrate concentrations in the absence of ferrocene was 
obtained, as presented in Table 4 and Figures 1 and 2.
Table 4. Initial reaction velocities of trypsin catalized hydrolysis
at various substrate concentrations
[S]
(mol/l)
[1/S]
(l/mol)
v
(µmol/lmin)
[1/v]
(mlmin/µmol)
14.15×10-5 70.67×102 4.87 205.339
27.17×10-5 36.81×102 10.07 99.305
70.75×10-5 14.13×102 19.99 50.025
113.20×10-5 8.83×102 29.46 33.944
236.31×10-5 4.23×102 48.12 20.781
353.75×10-5 2.83×102 54.87 18.225
b)  In the presence of ferrocene
The initial velocity at various substrate concentrations in the presence of ferrocene 
was obtained, as presented in Table 5 and Figures 1 and 2.
Table 5. Initial reaction velocities of trypsyn catalized hydrolysis
at various substrate concentrations in the presence of ferrocene
[S]
(mol/l)
[1/S]
(l/mol)
v
(µmol/lmin)
[1/v]
(mlmin/µmol)
14.17×10-5 70.57×102 5.41 184.843
27.22×10-5 36.74×102 10.29 97.182
70.86×10-5 14.11×102 20.91 47.824
113.44×10-5 8.82×102 28.98 34.507
236.41×10-5 4.23×102 46.83 21.354
354.28×10-5 2.82×102 47.70 20.964
Michaelis constant, Km = 2.121 mM (in the presence of ferrocene)
vmax = 85.68 (µmol/lmin) (in the presence of ferrocene)208
Fig. 1. Reaction velocities of trypsyn catalyzed hydrolysis versus [S] in the absence of
ferrocene (series 1 – full line) and in the presence of ferrocene (series 2 – dotted line) 
Fig. 2. Lineweaver/Burk plot for Michaelis constant determination in the absence of ferrocene
( full line) and in the presence of ferrocene (dotted line)
The data obtained from Figure 2:
- Michaelis  constant,  Km = 3.015 mM (in the absence of ferrocene)
-   vmax = 110.97 (µmol/lmin) (in the absence of ferrocene)
-   Michaelis constant, Km = 2.121 mM  (in the presence of ferrocene)
-   vmax =  85.68 (µmol/lmin) (in the presence of ferrocene)209
Determination of the inhibition constant (Ki ) for ferrocene 
Ki was determined by plotting the reaction velocity versus ferrocene concentration, 
at two different subs  trate concentrations, according to the experimental plan in Table 3. 
Results are presented in Table 6 and and Figure 3.
Table 6. Reaction velocities of trypsyn catalyzed hydrolysis at two different substrate concentra-
tions in the presence of various concentrations of ferrocene 
Ferrocene
µM
1 S v
(µmol/lmin)
[1/v] (S1)
(mlmin/µmol)
2 S v
(µmol/lmin)
[1/v] (S2)
(mlmin/µmol)
14.1444 46.24 21.649 45.94 21.768
21.3017 46.36 21.570
28.4590 42.35 23.661 45.15 22.148
35.3608 39.88 25.075
42.6033 39.26 23.702 43.31 23.089
     56.6984 38.68 25.858 38.56 25.934
70.8729 36.64 27.313 31.12 32.134
1 S v  - velocity of reaction inhibited by ferrocene at substrate concentration S1 
2 S v  - velocity of reaction inhibited by ferrocene at substrate concentration S2
Fig. 3. Lineweaver/Burk plot for the determination of Ki for ferrocene210
The inhibition constant for ferrocene determined from Figure 3: 
Ki  for ferrocene = 39.8 µM
Determination of the inhibition constant (Ki ) for benzamidine 
The inhibition constant for benzamidine was determined in the same manner as Ki for 
ferrocene, that is by plotting the reaction velocity versus benzamidine concentration, at 
two different substrate concentrations (data not shown).
It was determined that the inhibition constant for benzamidine is Ki= 10.58 µM.
The reaction rates (v) for the trypsin catalyzed hydrolysis of BAPNA, as well as Km, 
in the absence and in the presence of ferrocene were determined, and the obtained values 
were:
-  in the absence of ferrocene : v = 110.97 (µmol/lmin) and Km = 3.015 mM
-  in the presence of ferrocene : v= 85.68 (µmol/lmin) and Km = 2.121 mM.  
Also, the inhibition constants for ferrocene (Ki = 39.8 µM) and benzamidine (Ki = 
10.58 µM) were determined. 
Based on the obtained reaction rates and Km values, it can be concluded that ferrocene 
has an inhibitory effect on trypsin. These results are in accordance with the earlier reported 
results (35) with casein as a substrate (decrease in the enzyme activity was found to be ≈ 
25%).
It is obvious that ferrocene exhibits certain inhibitory effect on trypsin, although the 
inhibition type is not so obvious. The determination of Michaelis constant in the absence 
and in the presence of ferrocene (Fig.2) suggests a mixed-type inhibition (since the dou-
ble-reciprocal plots are intercepting in the positive quadrant) or  it could be that, besides 
the inhibitory effect, ferrocene also has an activating effect on trypsin (due to Fe2+). In that 
case, the observed effect of ferrocene on trypsin would be the combination of the two, with 
the inhibition prevailing.
The inhibition constant for ferrocene (Ki = 39.8 µM) was compared with the inhibition 
constant for benz  amidine, a standard competitive trypsin inhibitor (Ki =10.58 µM, under 
the same experimental conditi  ons). The positively charged nitrogen atom of benzamidine 
ﬁts into the pocket that determines the speci  ﬁcity of trypsin for positively charged amino 
acid residues (Lys and Arg), which is most likely the reason for the stronger inhibitory 
effect compared to ferrocene.  
Ferrocene’s modest inhibitory effect could be solely due to its ﬁve-coordinate geom-
etry and the intro  duction of the desirable functionalities in ferrocene derivatives in order to 
improve interaction with the enzyme’s active site (especially with the negatively charged 
carboxylate of the trypsin Asp 189 residue) would be the logical next step in the search 
for better inhibition.
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ИНХИБИЦИЈА ТРИПСИНА ФЕРОЦЕНОМ
Зоран З. Кукрић u Мирјана М. Жабић
Велики број прелазних метала и њихових комплекса може успјешно инхибирати 
дјеловање неких протеолитичких ензима као што је трипсин. Њихово инхибиторно 
дјеловање заснива се на директном везивању за активно мјесто трипсина имитирајући 
пентакоординатно прелазно стање потребно за реакцију. Из тог разлога изабран је 
фероцен, као потенцијални инхибитор, јер спада у органометалне сендвич спојеве 
чији циклопентадиенилни прстенови имају такву претпостављену геометрију.
У раду је испитиван утицај фероцена на активност трипсина са N-α-бензоил-
DL-aргинин p-нитроанилидом као супстратом. Утврђено је смањење активности 
трипсина и одређенa je кон  стан  тa инхибиције за фероцен, која је износи 39.8 µM.
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